HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease

Patients with Charcot-Marie-Tooth disease with predominant axonal loss (CMT2) show extensive genetic heterogeneity. Benoy et al. demonstrate a link between CMT2 and histone deacetylase 6 (HDAC6), which controls the acetylation of α-tubulin, and propose that pharmacological inhibition of HDAC6 has therapeutic potential in CMT2 genetic variants.

[1]  W. Robberecht,et al.  HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients , 2017, Nature Communications.

[2]  L. Bosch,et al.  Defective axonal transport: A common pathological mechanism in inherited and acquired peripheral neuropathies , 2017, Neurobiology of Disease.

[3]  B. Kalmar,et al.  Mitochondrial deficits and abnormal mitochondrial retrograde axonal transport play a role in the pathogenesis of mutant Hsp27-induced Charcot Marie Tooth Disease , 2017, Human molecular genetics.

[4]  Fang Yang,et al.  Acetylation of lysine ϵ-amino groups regulates aminoacyl-tRNA synthetase activity in Escherichia coli , 2017, The Journal of Biological Chemistry.

[5]  M. Z. Cader,et al.  PN07 Trk receptor signalling and sensory neuron fate are perturbed in human neuropathy caused by Gars mutations , 2017, Neuromuscular Disorders.

[6]  Hyunjung Choi,et al.  HDAC6 Inhibitors Rescued the Defective Axonal Mitochondrial Movement in Motor Neurons Derived from the Induced Pluripotent Stem Cells of Peripheral Neuropathy Patients with HSPB1 Mutation , 2016, Stem cells international.

[7]  W. Robberecht,et al.  Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot–Marie–Tooth Disease , 2016, Neurotherapeutics.

[8]  V. Baekelandt,et al.  Protection against Mitochondrial and Metal Toxicity Depends on Functional Lipid Binding Sites in ATP13A2 , 2016, Parkinson's disease.

[9]  R. Burgess,et al.  Synaptic Deficits at Neuromuscular Junctions in Two Mouse Models of Charcot–Marie–Tooth Type 2d , 2016, The Journal of Neuroscience.

[10]  G. Vistoli,et al.  Bicyclic-Capped Histone Deacetylase 6 Inhibitors with Improved Activity in a Model of Axonal Charcot-Marie-Tooth Disease. , 2016, ACS chemical neuroscience.

[11]  L. Van Den Bosch,et al.  Synthesis and SAR assessment of novel Tubathian analogs in the pursuit of potent and selective HDAC6 inhibitors. , 2016, Organic & biomolecular chemistry.

[12]  D. Chuang,et al.  Tubastatin A, an HDAC6 inhibitor, alleviates stroke-induced brain infarction and functional deficits: potential roles of α-tubulin acetylation and FGF-21 up-regulation , 2016, Scientific Reports.

[13]  L. Greensmith,et al.  Regulation of Axonal Transport by Protein Kinases. , 2015, Trends in biochemical sciences.

[14]  R. Burgess,et al.  CMT2D neuropathy is linked to the neomorphic binding activity of glycyl-tRNA synthetase , 2015, Nature.

[15]  Greg W. Clark,et al.  Panorama of ancient metazoan macromolecular complexes , 2015, Nature.

[16]  R. Burgess,et al.  Impaired protein translation in Drosophila models for Charcot–Marie–Tooth neuropathy caused by mutant tRNA synthetases , 2015, Nature Communications.

[17]  D. Pareyson,et al.  Mitochondrial dynamics and inherited peripheral nerve diseases , 2015, Neuroscience Letters.

[18]  K. De Bosscher,et al.  Synthesis of benzothiophene-based hydroxamic acids as potent and selective HDAC6 inhibitors. , 2015, Chemical communications.

[19]  S. Züchner,et al.  Impaired Function is a Common Feature of Neuropathy‐Associated Glycyl‐tRNA Synthetase Mutations , 2014, Human mutation.

[20]  A. Whitworth,et al.  Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations , 2014, Nature Communications.

[21]  L. Bosch,et al.  The role of histone deacetylase 6 (HDAC6) in neurodegeneration , 2014 .

[22]  K. Fischbeck,et al.  CMT-associated mutations in glycyl- and tyrosyl-tRNA synthetases exhibit similar pattern of toxicity and share common genetic modifiers in Drosophila , 2014, Neurobiology of Disease.

[23]  P. Verstreken,et al.  HDAC6 is a Bruchpilot deacetylase that facilitates neurotransmitter release. , 2014, Cell reports.

[24]  M. Z. Cader,et al.  Neuromuscular junction maturation defects precede impaired lower motor neuron connectivity in Charcot-Marie-Tooth type 2D mice. , 2014, Human molecular genetics.

[25]  Hua Zhu,et al.  Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice. , 2014, Journal of Alzheimer's disease : JAD.

[26]  S. Züchner,et al.  Exome sequencing identifies a significant variant in methionyl-tRNA synthetase (MARS) in a family with late-onset CMT2 , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[27]  J. Auwerx,et al.  Hdac6 deletion delays disease progression in the SOD1G93A mouse model of ALS. , 2013, Human molecular genetics.

[28]  Peng Yao,et al.  Charcot – Marie – Tooth disease : An inheritable human disease caused by mutations in cytoplasmic ARSs , 2013 .

[29]  J. Lupski,et al.  A Loss‐of‐Function Variant in the Human Histidyl‐tRNA Synthetase (HARS) Gene is Neurotoxic In Vivo , 2013, Human mutation.

[30]  O. Schlüter,et al.  Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease , 2012, EMBO molecular medicine.

[31]  M. Cilli,et al.  Electrophysiological features of the mouse tail nerves and their changes in chemotherapy induced peripheral neuropathy (CIPN) , 2012, Journal of Neuroscience Methods.

[32]  K. Fischbeck,et al.  Charcot-Marie-Tooth–Linked Mutant GARS Is Toxic to Peripheral Neurons Independent of Wild-Type GARS Levels , 2011, PLoS genetics.

[33]  B. Asselbergh,et al.  Small Heat-Shock Protein HSPB1 Mutants Stabilize Microtubules in Charcot-Marie-Tooth Neuropathy , 2011, The Journal of Neuroscience.

[34]  W. Robberecht,et al.  HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1–induced Charcot-Marie-Tooth disease , 2011, Nature Medicine.

[35]  R. Burgess,et al.  An assessment of mechanisms underlying peripheral axonal degeneration caused by aminoacyl-tRNA synthetase mutations , 2011, Molecular and Cellular Neuroscience.

[36]  Nancy F. Hansen,et al.  Compound heterozygosity for loss-of-function lysyl-tRNA synthetase mutations in a patient with peripheral neuropathy. , 2010, American journal of human genetics.

[37]  P. Schimmel,et al.  New functions of aminoacyl-tRNA synthetases beyond translation , 2010, Nature Reviews Molecular Cell Biology.

[38]  Kyle V. Butler,et al.  Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. , 2010, Journal of the American Chemical Society.

[39]  R. Durbin,et al.  Systematic Analysis of Human Protein Complexes Identifies Chromosome Segregation Proteins , 2010, Science.

[40]  E. Broussolle,et al.  A major determinant for binding and aminoacylation of tRNA(Ala) in cytoplasmic Alanyl-tRNA synthetase is mutated in dominant axonal Charcot-Marie-Tooth disease. , 2010, American journal of human genetics.

[41]  Kyle V. Butler,et al.  Rational Design and Simple Chemistry Yield a Superior , Neuroprotective HDAC 6 Inhibitor , Tubastatin A , 2010 .

[42]  M. Z. Cader,et al.  An ENU-induced mutation in mouse glycyl-tRNA synthetase (GARS) causes peripheral sensory and motor phenotypes creating a model of Charcot-Marie-Tooth type 2D peripheral neuropathy , 2009, Disease Models & Mechanisms.

[43]  Hongfang Liu,et al.  SpliceCenter: A suite of web-based bioinformatic applications for evaluating the impact of alternative splicing on RT-PCR, RNAi, microarray, and peptide-based studies , 2008, BMC Bioinformatics.

[44]  A. Grierson,et al.  Role of axonal transport in neurodegenerative diseases. , 2008, Annual review of neuroscience.

[45]  Sharon Y. R. Dent,et al.  HDAC6 modulates cell motility by altering the acetylation level of cortactin. , 2007, Molecular cell.

[46]  Xiang-Lei Yang,et al.  Charcot–Marie–Tooth disease-associated mutant tRNA synthetases linked to altered dimer interface and neurite distribution defect , 2007, Proceedings of the National Academy of Sciences.

[47]  Xiang-Lei Yang,et al.  Long-range structural effects of a Charcot–Marie–Tooth disease-causing mutation in human glycyl-tRNA synthetase , 2007, Proceedings of the National Academy of Sciences.

[48]  M. Reilly.  Sorting out the inherited neuropathies. , 2007, Practical neurology.

[49]  R. Burgess,et al.  An Active Dominant Mutation of Glycyl-tRNA Synthetase Causes Neuropathy in a Charcot-Marie-Tooth 2D Mouse Model , 2006, Neuron.

[50]  J. Thevelein,et al.  Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy , 2006, Nature Genetics.

[51]  G. Hennig,et al.  Characteristics of intermittent mitochondrial transport in guinea pig enteric nerve fibers. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[52]  Richard A Lewis,et al.  Motor unit number estimate of distal and proximal muscles in Charcot–Marie–Tooth disease , 2003, Muscle & nerve.

[53]  K. Fischbeck,et al.  Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. , 2003, American journal of human genetics.

[54]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[55]  B. Sefton,et al.  Protein kinases. , 1989, Cancer cells.

[56]  H. Skre,et al.  Genetic and clinical aspects of Charcot‐Marie‐Tooth's disease , 1974, Clinical genetics.